

Product Name: Thalidomide

Catalog No.: 0652 **Batch No.:** 11


CAS Number: 50-35-1

EC Number: 200-031-1

IUPAC Name: *N*-(2,6-dioxo-3-piperidiny)phthalimide

1. PHYSICAL AND CHEMICAL PROPERTIES

Batch Molecular Formula: C₁₃H₁₀N₂O₄
Batch Molecular Weight: 258.23
Physical Appearance: White solid
Solubility: DMSO to 25 mM
Storage: Store at RT
Batch Molecular Structure:



2. ANALYTICAL DATA

HPLC: Shows >99.9% purity
¹H NMR: Consistent with structure
Mass Spectrum: Consistent with structure

Microanalysis:

	Carbon	Hydrogen	Nitrogen
Theoretical	60.47	3.9	10.84
Found	60.6	3.86	10.8

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use

Tocris Bioscience is an R&D Systems company
 USA & CANADA Tel: (800) 343-7475 EUROPE Tel: +44 (0)1235 529449 CHINA Tel: +86 (21) 52380373
www.RnDSystems.com

R&D
SYSTEMS®

Product Name: Thalidomide

Catalog No.: 0652 **Batch No.:** 11

CAS Number: 50-35-1

EC Number: 200-031-1

IUPAC Name: *N*-(2,6-dioxo-3-piperidinyl)phthalimide

Description:

Teratogen, sedative-hypnotic with inherent anti-inflammatory properties. A selective inhibitor of tumor necrosis factor α (TNF- α) synthesis.

Physical and Chemical Properties:


Batch Molecular Formula: C₁₃H₁₀N₂O₄

Batch Molecular Weight: 258.23

Physical Appearance: White solid

Minimum Purity: >99%

Batch Molecular Structure:



Storage: Store at RT

Solubility & Usage Info:

DMSO to 25 mM

Stability and Solubility Advice:

Some solutions can be difficult to obtain and can be encouraged by rapid stirring, sonication or gentle warming (in a 45-60°C water bath).

Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide. Our standard recommendations are:

SOLIDS: Provided storage is as stated on the product label and the vial is kept tightly sealed, the product can be stored for up to 6 months from date of receipt.

SOLUTIONS: We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials at -20°C or below and used within 1 month. Wherever possible solutions should be made up and used on the same day.

References:

Merck Index **12** 9390.

Sampaio et al (1991) Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. *J.Exp.Med.* **173** 699. PMID: 1997652.

Makonkawkeyoon et al (1993) Thalidomide inhibits the replication of human-immunodeficiency-virus type 1. *Proc.Natl.Acad.Sci.U.S.A.* **90** 5974. PMID: 8327469.

Kanbayashi et al (1996) Thalidomide, a hypnotic with immune modulating properties, increases cataplexy in canine narcolepsy. *Neuroreport* **7** 1881. PMID: 8905685.

Boireau et al (1997) Thalidomide reduces MPTP-induced decrease in striatal dopamine levels in mice. *Neurosci.Lett.* **234** 123. PMID: 9364513.

Zhang et al (2008) Thalidomide influences growth and vasculogenic mimicry channel formation in melanoma. *J.Exp.Clin.Cancer Res.* **27** 60. PMID: 18983651.

Caution - Not Fully Tested • Research Use Only • Not For Human or Veterinary Use

Tocris Bioscience is an R&D Systems company
USA & CANADA Tel: (800) 343-7475 EUROPE Tel: +44 (0)1235 529449 CHINA Tel: +86 (21) 52380373
www.RnDSystems.com

R&D
SYSTEMS®